Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Sartorius AG
  6. News
  7. Summary
    SRT   DE0007165607

SARTORIUS AG

(SRT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sartorius : Releases the 5th Edition of its Popular Live-Cell...

10/05/2021 EST

Sartorius, a leader in new technologies for real-time, live-cell imaging and analysis, has released the 5th edition of its Live-Cell Analysis Handbook. When this handbook was first launched in 2017, it was a comprehensive reference guide for live-cell analysis technologies, focusing on the complete suite of Incucyte® live-cell assays and reagents. Over the years this handbook has been well received by Incucyte® users, generating over 3,000 requests of its 4th edition.

The live-cell applications covered in the Live-Cell Analysis Handbook include cell culture quality control assays and kinetic assays for cell health and proliferation, cell function, cell movement and morphology, and assays for complex 3D models. The 5th edition includes new sections on assays for evaluating embedded organoids, as well as exciting new data about mitochondrial membrane potential assays and differentiation, phagocytosis, and efferocytosis in immune cell models. Furthermore, this 5th edition includes a new chapter focused on advanced label-free cell analysis, such as the Incucyte® Cell-by-Cell Analysis and the new multi-variate classification analysis.

"Our latest edition highlights innovative, image-based machine learning to measure label-free cell counts, track differentiation of cells and even to determine mitotic cell cycle state. The power of this solution is the use of multi-variate analysis to continuously identify changes in cell symmetry, area, texture, circularity, perimeter length and solidity to automatically classify cells without the need to introduce a fluorescent label," said Lindy O'Clair, Head of BioAnalytics Applications, Reagents and Consumables. "Harnessing the power of the Incucyte® to study cells in a physiologically relevant environment and eliminating the need of a fluorescent probe, truly allows scientists to focus solely on the experimental variable, thus facilitating new discoveries."

The Incucyte® Live-Cell Analysis System enables real-time, kinetic monitoring of a range of cell types, from proliferating tumor cells to sensitive primary cells, all from within the cell culture incubator. Validated Incucyte® live-cell assays, reagents and protocols provide scientists with the tools to be able to explore more questions across a range of applications and research areas, without the limitations of laborious, end-point assays. Each year Sartorius scientists and product managers update this handbook to include the latest data and newest offerings in the Incucyte® live-cell assay portfolio.

To download the free 5th Edition Live-Cell Analysis Handbook, please visit:https://www.sartorius.com/live-cell-analysis-5th-edition-handbook

For more information on the Incucyte® system, please visit:www.sartorius.com/incucyte

Follow Sartorius on Twitter@Sartorius_Group and on LinkedIn.

Disclaimer

Sartorius AG published this content on 05 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 October 2021 13:11:04 UTC.


ę Publicnow 2021
All news about SARTORIUS AG
11/26Sartorius to Invest EUR100 Million in France by 2025, Create Up to 400 Jobs
DJ
11/25Sartorius to Invest Around EUR270 Million in South Korea Expansion
DJ
11/24Sartorius Significantly Expands Activities in South Korea
CI
11/18SARTORIUS : Opens Cell Culture Technology Center
PU
11/12SARTORIUS VORZUEGE : DZ Bank reiterates its Neutral rating
MD
11/11SARTORIUS VORZUEGE : Gets a Sell rating from UBS
MD
11/03Sartorius Honored as “Overall Best Bioprocessing Supplier” Award...
PU
11/01Sartorius Introduces Faster, Higher Capacity Sartolab« RF|BT...
PU
10/28SARTORIUS VORZUEGE : Berenberg remains Neutral
MD
10/27Waters and Sartorius Partner to Help Bioprocess Scientists...
PU
More news
Analyst Recommendations on SARTORIUS AG
More recommendations
Financials
Sales 2021 3 394 M 3 844 M 3 844 M
Net income 2021 411 M 466 M 466 M
Net Debt 2021 1 885 M 2 136 M 2 136 M
P/E ratio 2021 91,3x
Yield 2021 0,24%
Capitalization 39 338 M 44 339 M 44 562 M
EV / Sales 2021 12,1x
EV / Sales 2022 10,7x
Nbr of Employees 12 952
Free-Float 35,0%
Chart SARTORIUS AG
Duration : Period :
Sartorius AG Technical Analysis Chart | SRT | DE0007165607 | MarketScreener
Technical analysis trends SARTORIUS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 543,00 €
Average target price 483,55 €
Spread / Average Target -10,9%
EPS Revisions
Managers and Directors
Joachim Kreuzburg Chief Executive Officer
Rainer Lehmann Chief Financial Officer
Lothar Kappich Chairman-Supervisory Board
Oscar-Werner Reif Head-Research & Development
Volker Niebel Head-Production, Procurement & Business Operations
Sector and Competitors
1st jan.Capi. (M$)
SARTORIUS AG57.39%44 339
BIOTAGE AB (PUBL)94.68%1 967
REVENIO GROUP OYJ11.23%1 675
VAREX IMAGING CORPORATION71.16%1 126
CELLAVISION AB (PUBL)10.10%888
908 DEVICES INC.-57.86%670